Stable therapeutic radionuclide compositions and methods for preparation thereof
US5679318A · kind A · utility
20Cited by
9References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 21, 1994 |
| Grant date | Oct 21, 1997 |
| Priority date | — |
| Expiry date | Nov 21, 2014 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/866
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Stable therapeutic radionuclide compositions comprising, for example, .sup.186 Re, .sup.188 Re and .sup.131 I stably bound to a proteinaceous targeting moiety and suitable for human in vivo administration are disclosed. Stabilizing agents preferably comprise antioxidants and challenging agents, and combination of HSA with an antioxidant and/or challenging agent provides enhanced long term stability. Ascorbic acid is an especially preferred stabilizing agent, which provides stability of therapeutic radionuclide compositions at levels of at least about 90% for several hours up to several days.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.